Postnatal glucocorticoids in preterm neonates: use in French neonatal centres in 2006
- E Autret-Leca1,2,
- S Bauer3,
- C Alberti4,
- A P Jonville-Béra1,
- Y Aujard5,
- L Bensouda-Grimaldi1,2,
- O Baud5
- 1CHRU de Tours, Hôpital Bretonneau, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
- 2Université François Rabelais Tours, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
- 3CHRU de Tours, Hôpital Bretonneau, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
- 4Assistance Publique – Hôpitaux de Paris, Hôpital Robert Debré, Unité d’Epidémiologie Clinique, Paris, France
- 5Assistance Publique – Hôpitaux de Paris, Hôpital Robert Debré, Service de Réanimation et Pédiatrie Néonatales, Paris, France
- Professor E Autret-Leca, Service de Pharmacologie—CHRU de Tours—2 boulevard Tonnellé, 37044 Tours cedex 9, France; autret-leca{at}med.univ-tours.fr
In 1999, 80% of French neonatal centres used corticosteroids, mainly betamethasone, to prevent or to treat bronchopulmonary dysplasia (BPD).1 As many data suggested a low benefit/risk ratio, an updated assessment of this use was necessary.2–5
Methods
Questionnaires addressing the use of and indications for corticosteroids were sent to all French neonatal centres.
Results
The study was performed over five months (July–November 2006). Questionnaires were sent to 202 centres, of which 186 (92%) centres completed them. Of these 186 centres, 147 (79%) units had a standard protocol for corticosteroids use, …
